Hair Loss in Men and Women: Why It Looks Different

Summary

Pattern hair loss—androgenetic alopecia in men and female-pattern hair loss in women—is the most common cause of progressive hair thinning in adults. Both conditions share the same central biological mechanism: follicular miniaturization driven by androgen signaling against a background of genetic predisposition. Nevertheless, the clinical manifestations, hormonal context, typical age of onset, and diagnostic approach differ significantly between the sexes.

 This article describes these differences, ranging from the biology behind miniaturization and the regional androgen sensitivity that determines which areas thin out first, to the characteristic patterns in men and women, the life stages associated with onset or progression, and the diagnostic role of trichoscopy.

It also addresses the common clinical scenario in which telogen effluvium overlaps with underlying pattern hair loss, and presents a simple interpretive framework for distinguishing between these conditions during clinical evaluation. 

Understanding these gender-specific differences is clinically relevant. It lays the foundation for a more accurate diagnosis, a more productive clinical consultation, and a more targeted approach to treatment planning.

Introduction

Hair loss is one of the most common concerns among both patients and in dermatology practice, but it is not a single condition. Understanding what causes hair loss—and why it varies from person to person—is the starting point for any useful clinical evaluation.

Here, we’ll take a closer look at the most common form of hair loss, pattern hair loss, also known as androgenetic alopecia. We’ll delve deeply into the biology behind male-pattern baldness and why it manifests differently in men and women, what these differences look like in practice, and how clinicians and patients can distinguish male-pattern baldness from other forms of hair loss.

We cover the mechanism behind follicular miniaturization, the hormonal basis for sex-specific patterns, characteristic clinical presentations, the diagnostic role of trichoscopy, and a simple framework for interpreting clinical findings.

Why It Looks Different

Androgenetic alopecia is the most common cause of hair thinning in both men and women.

However, the way the condition manifests itself differs between male-pattern hair loss and female-pattern hair loss. In men, androgen signaling plays a central role, and the term AGA is the standard. In women, the term female pattern hair loss (FPHL) is often used to reflect the fact that factors other than androgen signaling may also contribute.

Despite this, the underlying mechanism is the same in both sexes: follicular miniaturization.

It is this single process—and not a sudden increase in hair shedding—that defines male-pattern hair loss and distinguishes it from diffuse hair loss conditions such as telogen effluvium, which will be discussed later. [1,3] Follicular miniaturization is the defining biological process in androgenetic alopecia. Every clinical feature described in AGA—the gradual thinning, the characteristic distribution, and the differences between men and women—results from this process. Understanding miniaturization is essential to understanding male-pattern hair loss.

Although men and women share this mechanism, the way hair thinning manifests itself differs. These differences are influenced by regional variations in hormonal sensitivity in the scalp, the relative balance between androgens and estrogens, and genetic factors that determine where and how hair thinning develops. [1–4]

How common is pattern hair loss?

Pattern hair loss is very common, and its prevalence clearly increases with age in both sexes.

In women, clinically detectable female-pattern hair loss affects approximately 3 to 12 percent of those in their 20s and 30s, rising to 14 to 28 percent in their 50s and up to 56 percent among those over 70. Lower prevalence has been reported among Asian women. [1,7]

Among men, the prevalence is much higher, but follows a similar age-related pattern. Approximately 16 to 20 percent of men aged 18 to 29 have detectable hair loss. This increases to about 30 percent by age 30, 40 to 50 percent by ages 40 to 50, and over 70 to 80 percent by ages 70 to 80. The condition is more common among Caucasian men than in Asian or African populations. [2,3,10,13]

Family history is a common risk factor in both sexes. Several genes are involved, including genes that regulate the sensitivity of androgen receptors. In men, the mode of inheritance is often clearly maternal, with X-linked variants in the androgen receptor playing a documented role. In women, the genetic picture is less clear-cut and does not follow the same pattern. [1,9]

What Actually Happens: Follicular Miniaturization

Hair follicles continuously go through phases of growth (anagen), a short transitional phase (catagen), and rest (telogen). In a healthy hair follicle, the growth phase is long, and each new hair grows back with roughly the same thickness. In pattern hair loss, this cycle continues, but the hair follicle itself gradually shrinks with each new cycle.

This is miniaturization. With each new cycle, the affected hair follicle produces a hair that is slightly thinner, slightly shorter, and slightly less pigmented than the previous one. The active growth phase becomes shorter, and the resting phase before the next cycle becomes longer. The hair follicle is not destroyed; it is still present and still functioning, but production is gradually reduced. Over time, thick, pigmented terminal hairs are replaced by finer, shorter, and less visible hairs. [1,3,5]

The most important clinical consequence is that hair density appears to decrease even when the number of hairs shed daily is completely normal. Therefore, pattern hair loss is often not noticeable at first. There is no dramatic increase in the amount of hair on the pillow or in the shower. Instead, a gradual replacement occurs, in which each hair grows back slightly weaker than before, until a threshold is reached and the scalp becomes more visible. [1,3]

Miniaturization produces characteristic findings, which are discussed in more detail below. It is these findings that enable clinicians to confirm AGA and distinguish it from other causes of hair thinning.

At the follicular level, miniaturization can be viewed as:

1. A reduction in hair shaft diameter and increasing variation in thickness, with fine hairs appearing side by side with thicker hairs in the same area

2. Fewer hairs per follicular unit, with single-hair openings increasingly replacing the natural clusters of 2 to 3 hairs

3. Preserved follicular ostia, where the openings are still visible, confirming that the hair follicles are present and are miniaturizing, not being destroyed [1,4,12]

Hormonal Drivers and Androgen Sensitivity

DHT and Androgen Signaling

Pattern hair loss is not caused by abnormally high testosterone levels. Most men and women with AGA have completely normal circulating androgen levels. What differs is how individual hair follicles react locally to androgens.

In the skin, testosterone is converted by the enzyme 5α-reductase into dihydrotestosterone (DHT), a more potent androgen. In genetically susceptible hair follicles, DHT binding to androgen receptors gradually inhibits follicular activity, shortens the growth phase, and drives the miniaturization process. [1,3,6] Sensitivity varies both between individuals and between areas of the scalp, which explains both who develops AGA and where on the scalp it first appears.

Why some areas are becoming sparser while others are spared

The regional selectivity of pattern hair loss reflects differences in androgen sensitivity in the hair follicles across the scalp. Hair follicles in the forehead and crown areas have higher levels of androgen receptors and greater 5α-reductase activity than those at the back of the head. This enzymatic gradient—rather than a systemic hormonal imbalance—explains why the back and sides of the scalp are typically spared. [5]

In women, an additional enzyme—aromatase—also plays a role. Aromatase converts testosterone into estradiol, thereby reducing local androgenic effects. Hair follicles on the forehead in women have approximately six times higher aromatase activity than in men, which partly explains why the frontal hairline is usually preserved in women with female-pattern hair loss. [1,5,8] Estrogen also supports the hair growth phase independently of this, which is why hormonal changes during menopause often coincide with the progression of female pattern hair loss in predisposed women. [1,8]

What Pattern Hair Loss Looks Like Clinically: A Comparison of Men and Women

The clinical difference between male-pattern and female-pattern hair loss is not merely a matter of degree. It reflects a real difference in where and how miniaturization manifests itself, shaped by the hormonal differences described above.

In men

Male-pattern hair loss typically begins with a receding hairline at the front and temples, thinning on the crown, or both at the same time. Over time, these two areas expand and may merge, in line with the stages described in the Norwood classification. Because changes in the hairline become visible relatively early, even before the overall loss of hair density is significant, men often notice and seek help for male pattern hair loss at a relatively early stage. The sides and back of the head are usually spared throughout the course of the condition, consistent with lower androgen sensitivity in these areas. [2,3,10]

In women

Female-pattern hair loss manifests differently and more subtly. The frontal hairline is usually preserved, often until the condition is well advanced. Instead, thinning is concentrated in the center of the scalp, resulting in a characteristic wider part and, in some cases, a Christmas tree-like pattern with diffuse thinning at the front. Because there is no easily recognizable change in the hairline, female pattern hair loss is often overlooked or downplayed in its early stages. [1,7,8]

Early signs are easy to overlook: a ponytail that feels thinner, a more visible scalp in direct light, or greater difficulty achieving volume when styling. These changes may have been present for several years before the patient even perceives them as hair loss. The Ludwig classification describes the degree of severity, but in practice it is more clinically relevant to assess whether miniaturization is present, because this is what distinguishes female pattern hair loss from other causes of diffuse hair thinning. [1,11]

Overlap: when pattern hair loss and seasonal hair shedding occur at the same time

One of the most common and important clinical scenarios in practice is the coexistence of pattern hair loss and telogen effluvium, and understanding this helps prevent misdiagnosis in both directions.

Telogen effluvium is a distinct and common cause of hair loss, in which a physiological stressor—such as illness, surgery, significant weight loss, childbirth, or a change in medication—causes a large number of hair follicles to prematurely enter the resting phase (telogen), leading to diffuse hair loss weeks to months later. TE is reversible and does not involve miniaturization. Androgenetic alopecia, on the other hand, is progressive and characterized by miniaturization. The two conditions can occur independently of each other or simultaneously.

What makes this clinically significant is the timing. In a patient with underlying female-pattern hair loss that has developed gradually over several years, an acute stressor can trigger an episode of telogen effluvium that makes the existing hair thinning suddenly and dramatically visible. The patient seeks help because of what is perceived as sudden and severe hair loss, but trichoscopy reveals pre-existing miniaturization that was present before the acute episode. TE is acute and will resolve on its own. Female-pattern hair loss will not resolve on its own without treatment.

This scenario is particularly common in women, especially in the postpartum period, following significant weight loss—including weight loss achieved through the use of GLP-1 receptor agonists, which are now widely used in weight management and can trigger TE through rapid calorie restriction— and during perimenopause. Recognizing both components changes the clinical conversation. It distinguishes what is temporary from what requires long-term follow-up, and avoids both downplaying the concern by explaining everything away as transient TE and causing unnecessary alarm by interpreting TE as a serious progressive hair disorder. [1,7,14]

When pattern hair loss typically begins or progresses

In women, several life stages are associated with the onset or increased visibility of female-pattern hair loss—not as causes in and of themselves, but as periods during which hormonal changes or physiological stress interact with an underlying predisposition:

1. Puberty and early adulthood: Female-pattern hair loss can begin as early as the late teens or in the 20s in predisposed women, when androgen levels stabilize at adult levels. [1]

2. Polycystic ovary syndrome (PCOS): Early-onset female-pattern hair loss, particularly when accompanied by signs of androgen excess—such as irregular menstrual cycles, acne, and hirsutism—should prompt a hormonal evaluation. Elevated androgen levels may directly contribute to miniaturization in these patients. [1,7]

3. The postpartum period: Estrogen levels drop sharply after childbirth, triggering widespread telogen hair shedding. In predisposed women, this phase may also reveal underlying female-pattern hair loss that was previously masked by estrogen’s growth-promoting effect. [1,14]

4. Menopause: The decline in estrogen beginning in the late 40s and continuing thereafter shifts the balance between androgens and estrogens and increases the relative effect of androgen signaling on vulnerable hair follicles. Progression of female-pattern hair loss during this period is common. [1,7]

Atypical presentations

Not all patients follow the expected pattern. Some women develop temporal recession similar to male-pattern hair loss, and when this occurs alongside other signs of androgen excess, further hormonal evaluation is warranted. Some men experience more diffuse hair thinning without the classic frontal receding hairline or thinning on the crown. [1,3,4]

Atypical presentations serve as a useful reminder that pattern hair loss is a clinical diagnosis that depends on confirming miniaturization, not on the findings fitting neatly into a classification system. Trichoscopy, as described below, is particularly valuable in such cases.

Why hair loss that has developed over several years often feels sudden

Because miniaturization develops over several hair growth cycles, the biological process behind pattern hair loss is usually well underway before the person even notices it. The process takes place at the follicle level: androgen signaling inhibits the activity of the hair follicle, the growth phase is shortened, and individual hairs gradually become finer. None of this is visible. [1,3]

What triggers awareness is a threshold—the point at which enough hair follicles produce hair that is sufficiently thin for the scalp to become more visible, the part to widen, or styling to become noticeably more difficult. The experience of sudden hair loss is real, but it reflects the moment of discovery, not the start of the process. The biological process began earlier, without being visible. [1,3]

This difference has direct practical implications. Early detection of pattern hair loss, before hair density has declined significantly, gives available treatments the best chance of slowing its progression. The most well-established treatments for AGA, including topical and oral therapies, work primarily by slowing progression and supporting existing follicular function, rather than restoring hair that has already undergone miniaturization. Waiting until the change is visually apparent means that a larger proportion of the hair follicles have already undergone irreversible miniaturization.

Trichoscopy: Why It's Important and What It Shows

Trichoscopy—a magnified examination of the scalp and hair shafts—is not just a way to take a closer look. It is the most reliable non-invasive method for confirming the presence of follicular miniaturization. This single finding is what distinguishes AGA from telogen effluvium at the follicular level, and its presence or absence influences both diagnosis and treatment recommendations.

The most important trichoscopic findings in AGA are:

1. Variation in hair shaft diameter: The visual hallmark of miniaturization. When fine, vellus-like hairs appear alongside normal terminal hairs in the same area, miniaturization is occurring. In TE without AGA, the hair shafts are roughly uniform in diameter.

2. An increased proportion of fine or vellus hair in the affected area, reflecting the gradual replacement of terminal hair

3. Reduced number of hairs per follicular unit: More units with a single hair, fewer natural groups of 2 to 3 hairs—a direct indication of reduced follicular production

4. Preserved follicular ostia: The follicular openings remain visible, confirming that the hair follicles are intact but have become miniaturized, rather than destroyed as in scarring alopecia [12]

Trichoscopy: Why It's Important and What It Shows (cont.)

In women, it is particularly useful to compare the forehead or crown area with the back of the head. In female pattern hair loss, there is a gradient from the front to the back of the head: variation in diameter and vellus hair is more pronounced at the front, while the back of the head shows more uniform hair strands of normal thickness. This gradient supports the diagnosis of female pattern hair loss. In diffuse TE without AGA, the hair strands tend to be more uniform in diameter across all regions.

The combination of regional patterns—that is, where thinning occurs—follicular miniaturization as seen on trichoscopy, and clinical history, such as the rate of progression, family history, and triggering events, usually makes it possible to make a definitive diagnosis without the need for a biopsy.

How this is applied in practice: a simple diagnostic framework

The biological and clinical characteristics described above can be translated into a simple interpretive framework. Most cases of hair loss fall into one of three categories:

Pattern + progressive + miniaturization → AGA or female-pattern hair loss

Hair thinning follows a characteristic pattern: on the crown and temples in men, and along the central parting in women. Trichoscopy confirms variations in hair shaft diameter and the presence of vellus hair in the affected areas. The onset is gradual over several years, and a family history is common. This is the clinical hallmark of androgenetic alopecia.

Diffuse, acute, uniform strands of hair → telogen effluvium

Hair loss is generalized and often of a concerning extent. The onset is recent and typically follows a clear triggering factor, such as illness, surgery, childbirth, rapid weight loss, or a change in medication. Trichoscopy reveals a relatively uniform hair shaft diameter without the variation characteristic of miniaturization. The process is reversible once the triggering factor subsides.

Both at the same time—the most common situation in practice

An acute episode of TE makes pre-existing but previously subtle AGA suddenly noticeable. The patient experiences sudden and severe hair loss, while trichoscopy reveals both an increased proportion of telogen hairs and underlying miniaturization. In women, this overlap is particularly common after childbirth, after weight loss, and during perimenopause. The most important clinical task is not to choose between the diagnoses, but to recognize both, because they have different prognoses and require different consultations and interventions.

When Blood Tests Are Relevant

Blood tests are not necessary for all cases of pattern hair loss, although recommendations vary. Some recommend that evaluation for androgen excess should be considered in all women with female-pattern hair loss, regardless of whether symptoms of androgen excess are present. [7] Other approaches are more selective and reserve testing for situations where the clinical picture specifically suggests a contributing factor beyond genetics alone, such as signs of androgen excess, irregular menstrual cycles, acne and hirsutism, early or atypical onset, features suggestive of thyroid disease, or a history of significant dietary restriction or rapid weight loss. [1,2]

In such situations, targeted testing can identify correctable factors contributing to hair loss, even when the underlying AGA itself is not reversible. Key parameters to evaluate include ferritin, a complete blood count, thyroid function, and, in women with signs of androgen excess, relevant hormone markers. Iron deficiency is the most consistently implicated nutritional factor in diffuse hair loss, particularly in women of childbearing age. Vitamin D deficiency is also common and worth evaluating. Correcting actual deficiencies can reduce the overall severity of hair loss, even though it does not alter the underlying genetic process of miniaturization. [1,2]

Conclusion

Pattern hair loss is defined by follicular miniaturization, a process that is progressive, biologically driven, and usually well underway before it becomes visible. In men, it follows a recognizable pattern characterized by receding hairline and thinning on the crown. In women, it results in more diffuse central thinning with relative preservation of the frontal hairline, and it is more likely to remain undetected in the early stages.

The gender-specific differences in presentation, hormonal context, and natural course are not coincidental. They influence how the condition is detected, when further evaluation is necessary, and what the treatment discussion should cover. Trichoscopy is the most important tool for confirming miniaturization and distinguishing pattern hair loss from other causes of hair thinning, particularly telogen effluvium, which often occurs concurrently with underlying AGA and must be recognized as a distinct but overlapping process.

Applying this understanding—miniaturization as the central mechanism, the pattern as a diagnostic clue, and trichoscopy as a confirmatory tool—provides both clinicians and informed patients with a coherent framework for understanding what they see. This framework also serves as the basis for selecting the appropriate treatment: knowing whether miniaturization is present, how far it has progressed, and whether concurrent telogen effluvium is a contributing factor shapes both the treatment plan and the discussion of expectations.

References

1. Olsen EA. Hair Loss in Women. N Engl J Med. 2025;393(15):1509–1520. doi:10.1056/NEJMcp2412146

2. Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and men, short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22. doi:10.1111/jdv.14624

3. Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; updated Jan. 25, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278957/

4. Blume-Peytavi U, Blumeyer A, Tosti A, et al. S1 guideline for the diagnostic evaluation of androgenetic alopecia in men, women, and adolescents. Br J Dermatol. 2011;164(1):5–15. doi:10.1111/j.1365-2133.2010.10011.x

5. Sawaya ME, Price VH. Different levels of 5α-reductase types I and II, aromatase, and androgen receptor in the hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997;109(3):296–300. doi:10.1111/1523-1747.ep12335779

6. Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. Exp Dermatol. 2013;22(3):168–171. doi:10.1111/exd.12024

7. Carmina E, Azziz R, Bergfeld W, et al. Female-pattern hair loss and androgen excess: a report from the multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019;104(7):2875–2891. doi:10.1210/jc.2018-02548

8. Ramos PM, Miot HA. Female Pattern Hair Loss: A Clinical and Pathophysiological Review. An Bras Dermatol. 2015;90(4):529–543. doi:10.1590/abd1806-4841.20153370

9. Heilmann-Heimbach S, Herold C, Hochfeld LM, et al. A meta-analysis identifies novel risk loci and provides systematic insights into the biology of male-pattern baldness. Nat Commun. 2017;8:14694. doi:10.1038/ncomms14694

10. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359–1365. doi:10.1097/00007611-197511000-00009

11. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in women. Br J Dermatol. 1977;97(3):247–254. doi:10.1111/j.1365-2133.1977.tb15179.x

12. Kuczara A, Waśkiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Trichoscopy of androgenetic alopecia: A systematic review. J Clin Med. 2024;13(7):1962. doi:10.3390/jcm13071962

13. Sinclair R. Male-pattern androgenetic alopecia. BMJ. 1998;317(7162):865–869. doi:10.1136/bmj.317.7162.865

14. Piérard-Franchimont C, Piérard GE. Alterations in hair follicle dynamics in women. Biomed Res Int. 2013;2013:957432. doi:10.1155/2013/957432